p16 marker study in colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at a marker called p16 in colorectal cancer tissue. It aims to find out if p16 is linked to how the disease behaves, which could help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer.
- You must have a tissue sample from surgery or biopsy that is big enough and not damaged or dead.
- Your medical records must have enough information about your case (like test results and history).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a feature of colorectal cancer called tumor budding, which may help doctors understand how the cancer behaves. It does not involve new treatments but may provide information that could guide care.
This study looks at special tiny cell-signal particles (called exosomes) and related pathways to understand colorectal cancer. Your results from samples may help researchers learn how these signals relate to the disease after surgery.
This study looks at how the immune system reacts to colorectal cancer in the body. It aims to understand immune responses better, which may help improve future treatments.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
This study looks at colorectal cancer patients who are planning curative surgery and collects related outcomes and lab “biomarker” information to better understand the disease. Your participation may help researchers connect test results to treatment results over time.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.